2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1521

A Possible Contribution of Decreased Cathepsin V Expression to the Development of Dermal Fibrosis, Proliferative Vasculopathy, and Altered Keratinocyte Phenotype in Systemic Sclerosis
Abstract Number: 1504

A Possible Contribution of Visfatin to the Resolution of Skin Sclerosis in Patients with Diffuse Cutaneous Systemic Sclerosis Via a Direct Anti-Fibrotic Effect On Dermal Fibroblasts and Th1 Polarization of the Immune Response
Abstract Number: 103

A Pragmatic Musculoskeletal Ultrasound Screening Protocol Does Not Add to a Predictive Algorithm for Persistent Inflammatory Arthritis in a UK Early Arthritis Clinic
Abstract Number: 765

A Prediction Rule for the Development of Rheumatoid Arthritis: A Prospective Cohort Study of Seropositive Arthralgia Patients
Abstract Number: 2096

A Prediction Rule for the Progression to Rheumatoid Arthritis Applied in a Mexican Mestizo Cohort with Undifferentiated Arthritis
Abstract Number: 2405

A Proof-of-Concept Study of an Animated, Web-Based Methotrexate Decision Aid for Patients with Rheumatoid Arthritis
Abstract Number: 2425

A Qualitative Study of Self-Image and Body Image in Individuals with Systemic Lupus Erythematosus
Abstract Number: 1108

A Randomized Controlled Trial of Hylan G-F 20 for the Treatment of Carpometacarpal Osteoarthritis
Abstract Number: 2473

A Randomized Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine Versus Prednisone Plus Methotrexate
Abstract Number: 2545

A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Tocilizumab SC Versus Tocilizumab IV, in Combination with Traditional Dmards in Patients with Moderate to Severe RA
Abstract Number: L8

A Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Tocilizumab Subcutaneous Versus Placebo in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis (BREVACTA)
Abstract Number: 831

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Abstract Number: 2472

A Randomized, Multicentre, Double Blind, Placebo-Controlled Trial of Anti TNF Alpha (adalimumab) in Refractory Hand Osteoarthritis: The Dora Study
Abstract Number: 549

A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II
Abstract Number: L1

A Randomized, Placebo-Controlled Phase 2 Study of ARRY-797 in Patients with Osteoarthritis Pain Refractory to NSAID Treatment Showed Statistically Significant Improvements in WOMAC Pain and in Biomarkers of Bone and Cartilage Degradation

« Previous Page
1
…
4
5
6
7
8
…
180
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].